Compare JPMorgan Diversified Return International Eqty ETF (JPIN) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Diversified Return International Eqty ETF vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? JPMorgan Diversified Return International Eqty ETF trades at $73 (market cap $380.28M), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: Maravai LifeSciences Holdings Inc. Class A Common Stock is far larger — about 2.6× JPMorgan Diversified Return International Eqty ETF's market cap, and JPMorgan Diversified Return International Eqty ETF is more actively traded (4,689 versus 2,742,564). Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Diversified Return International Eqty ETF for 121 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| JPIN | MRVI | |
|---|---|---|
Market Cap | $380.28M | $977.37M |
Volume | 4,689 | 2,742,564 |
52-Week High | $77.80 | $9.00 |
52-Week Low | $65.86 | $2.83 |
Typical Hold Time | 121 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPIN trades at $73.52, up 0.65% with bearish technical signals dominating. The ETF shows oversold RSI readings but faces strong selling pressure across moving averages and ADX indicators. Support and resistance cluster tightly around $73-74, suggesting potential for near-term volatility. Recent dividend announcement for September 2026 provides future income potential.
The ETF's outlook remains challenged by bearish momentum despite oversold conditions. Investment opportunity exists for value investors seeking international equity exposure, though risks include continued technical weakness and market volatility. The concentrated price action around current levels indicates potential breakout or breakdown scenario ahead.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
